Metrics as of 10/16/2026, 10:43 AM (Berlin time), refresh in progress.
Elicio Therapeutics Stock
Elicio Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Robert T. Connelly
- Employees
- 33
- Market cap
- $34 M
- IPO
- 05/02/2021
- Web
- elicio.com
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven…
Elicio Therapeutics stock: price history
1D
-0.6%
1W
-1.7%
1M
-10.6%
6M
-85.9%
YTD
-77.6%
1Y
-83.2%
2Y
-60.4%
5Y
–
10Y
–
Next earnings date
Next earnings date
12/11/2026 (in 26 days)
Volatility around earnings
~28% weaker price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vsqueeze-release-v1.0 on 16/10/26. Not a buy or sell signal.Beta
What does this mean?
Volatility squeeze
BearishPrice swings had compressed unusually tight beforehand (volatility near a low) and are now releasing into a stronger move. Technical analysis views such tight phases as often preceding a bigger move.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Elicio Therapeutics
Analyst assessment of Elicio Therapeutics
PRICE TARGET LOW
US$1.50
CONSENSUS
US$11.83
MEDIAN
US$17.00
PRICE TARGET HIGH
US$17.00
0
STRONG BUY
2
BUY
2
HOLD
0
SELL
0
STRONG SELL
4
TOTAL · Buy
As of: 24/09/2026
Elicio Therapeutics stock metrics
P/E
-0.84
P/B
4.32
EV/EBITDA
-0.61
RETURN ON EQUITY
-103.5%
NET MARGIN
0.0%
DEBT/EQUITY
1.78
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
46.6%
FLOAT SHARES
8,884,153
AVG. DAILY VOLUME (30D)
328,092
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Elicio Therapeutics stock
What does Elicio Therapeutics do?
Elicio Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Robert T. Connelly, the company employs around 33 people.
The IPO was on 05/02/2021; the stock trades on NASDAQ under the ticker ELTX.
What do analysts say about Elicio Therapeutics stock?
4 analysts rate the stock, the consensus is Buy (as of 24/09/2026).
The average price target is US$11.83, ranging from US$1.50 to US$17.00, with a median of US$17.00.
This is an external assessment, not a statement by Market Jury.
When does Elicio Therapeutics report next?
The next earnings date is 12/11/2026.
Around past earnings, price swings were roughly -28% stronger than usual.
Does Elicio Therapeutics pay a dividend?
No, Elicio Therapeutics currently does not pay a dividend.
Which stocks are comparable to Elicio Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Elicio Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess Elicio Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.